[Plasma levels of diphenylhydantoin (DPH) and phenobarbitone (PB) in epileptic patients resistant to drug treatment (author's transl)]. 1977

G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci

The Authors present and discuss the results obtained by assaying plasma DPH and PB in 123 patients chronically treated with antiepileptic drugs. The subjects examined were considered resistant to medical therapy and were all at their first laboratory control. The data obtained show: 1) the very poor correlation existing between the doses of drugs administered and their actual plasma levels; 2) the very high percentage of patients with DPH and PB plasma levels not in the therapeutic range of these drugs. The Authors discuss some of the most frequent errors in planning chronic therapy with DPH and barbiturates due to the lack of knowledge of drug blood levels.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
October 1977, British journal of clinical pharmacology,
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
January 1976, Proceedings of the Australian Association of Neurologists,
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
May 1983, Boletin medico del Hospital Infantil de Mexico,
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
September 1981, EEG-EMG Zeitschrift fur Elektroenzephalographie, Elektromyographie und verwandte Gebiete,
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
January 1981, Wiener medizinische Wochenschrift (1946),
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
January 1977, Folia psychiatrica et neurologica japonica,
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
September 1974, Harefuah,
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
July 1979, Revista medica de Chile,
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
December 1971, Minerva pediatrica,
G Zaccara, and A Galli, and L Rossi, and R Zappoli, and L Zatelli, and L Amaducci
January 1972, Revue de neuropsychiatrie infantile et d'hygiene mentale de l'enfance,
Copied contents to your clipboard!